NDA 204516 · Legacy
Brisdelle
Paroxetine Mesylate · Oral
Last checked: Nov 19, 2026Latest source record: Feb 11, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2013
Jun 28, 2013
Approved uses
1
Original approval plus efficacy supplements
Registered trials
275
60 Phase 3, 11 recruiting
FAERS reports
34,264
28,096 serious, 4,456 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: SUICIDAL THOUGHTS AND BEHAVIORS Selective serotonin reuptake inhibitors (SSRIs) increased the risk of suicidal thoughts and behavior in pediatric and young adult patients in short-term trials for the treatment of major depressive disorder and other psychiatric disorders. Because BRISDELLE is an SSRI, closely monitor BRISDELLE-treated patients closely for emergence of suicidal thoughts and behaviors [see Warnings and Precautions ( 5.1 )] . BRISDELLE is not approved for use in any psychiatric condition or in pediatric and young adult patients [see Indications and Usage ( 1 ) and Use in Specific Populations ( 8.4 )] . WARNING: SUICIDAL THOUGHTS AND BEHAVIORS See full prescribing information for complete boxed warning. Antidepressants, including selective serotonin reuptake inhibitors (SSRIs), increased the risk of suicidal thoughts and behavior in pediatric and young adult...
What it is approved for
From the label in effect Apr 28, 2025.
BRISDELLE is indicated for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause. Limitations of Use: BRISDELLE is not indicated for the treatment of any psychiatric condition. BRISDELLE has a lower recommended paroxetine dosage than that used to treat major depressive disorder, obsessive compulsive disorder, panic disorder, generalized anxiety disorder, social anxiety disorder, and post-traumatic stress disorder. The safety and effectiveness of the lower BRISDELLE dosage has not been established for any psychiatric condition. Patients who require paroxetine for treatment of a psychiatric condition should discontinue BRISDELLE and initiate a paroxetine-containing product that is indicated for such use. BRISDELLE is a selective serotonin reuptake inhibitor (SSRI) indicated for the treatment of moderate to severe vasomotor symptoms associated with menopause (VMS) ( 1 ) Limitations of Use : BRISDELLE is not indicated for the treatment of any psychiatric condition ( 1 )
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 28, 2013 Original approval · Type 3 - New Dosage Form LabelReviewSummary Review
1 products under this application
- BRISDELLE · PAROXETINE MESYLATE EQ 7.5MG BASE · CAPSULE, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Paroxetine" as an intervention, any sponsor and status, largest first.
- Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD)Pivotal-lookingCompleted
National Institute of Mental Health (NIMH)NIH
NCT00012558 · 5,000 participants · Start Sep 1998
Drug: lithium; valproate and 6 more · For: Bipolar Disorder
Sites: Stanford, California; Denver, Colorado; Boston, Massachusetts · 11 sites in all
- Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial)Pivotal-lookingCompleted
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT01360866 · 2,944 participants · Start Oct 2011 · Primary completion Apr 18, 2017
Drug: OPC-34712; Escitalopram and 5 more · For: Depressive Disorder; Depression; Depressive Disorder, Major and 2 more
Sites: Birmingham, Alabama; Phoenix, Arizona; Little Rock, Arkansas · 142 sites in all
Peking UniversityAcademic, hospital or other
NCT02023567 · 2,400 participants (planned) · Start Nov 2013 · Primary completion Dec 2016
Drug: SSRIs · For: Depressive Disorder, Major
Sites: Beijing, China; Shijiazhuang, China; Dalian, China · 9 sites in all
- Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant TreatmentPivotal-lookingCompleted
H. Lundbeck A/SIndustry
NCT01838681 · 1,986 participants · Start Jun 2013 · Primary completion Jun 2016
Drug: Placebo; Brexpiprazole and 1 more · For: Major Depressive Disorder
Sites: Little Rock, Arkansas; Cerritos, California; Temecula, California · 107 sites in all
BioNTech SEIndustry
NCT07070232 · 1,438 participants (planned) · Start Aug 12, 2025 · Primary completion Mar 2028
Drug: BNT326; Pumitamig and 2 more · For: Advanced Solid Tumor
Sites: Phoenix, Arizona; San Francisco, California; Hartford, Connecticut · 79 sites in all
- A Trial to Evaluate the Efficacy, Safety & Tolerability of Brexpiprazole in the Maintenance Treatment of Adults With Major Depressive DisorderPivotal-lookingCompleted
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT03538691 · 1,149 participants · Start Jul 13, 2018 · Primary completion Jul 8, 2022
Drug: Brexpiprazole; Antidepressant therapy · For: Major Depressive Disorder
Sites: Los Angeles, California
- Algorithm Guided Treatment Strategies for Major Depressive DisorderPivotal-lookingStatus unknown
Shanghai Mental Health CenterAcademic, hospital or other
NCT01764867 · 1,080 participants (planned) · Start Jun 2012 · Primary completion Oct 2014
Drug: Escitalopram; Mirtazapine and 11 more · For: Major Depressive Disorder
Sites: Shanghai, China
- Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)Pivotal-lookingCompleted
Forest LaboratoriesAbbVie (ABBV)
NCT01715805 · 1,022 participants · Start Nov 15, 2012 · Primary completion Jun 24, 2016
Drug: Cariprazine; Placebo and 1 more · For: Major Depressive Disorder
Sites: Tucson, Arizona; Little Rock, Arkansas; Cerritos, California · 85 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective2,117
- drug interaction1,913
- fatigue1,894
- nausea1,790
- toxicity to various agents1,649
- diarrhoea1,527
- anxiety1,516
- headache1,499
- dizziness1,405
- off label use1,396
- fall1,328
- drug abuse1,299
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 133 |
| 2005 | 108 |
| 2006 | 176 |
| 2007 | 519 |
| 2008 | 170 |
| 2009 | 193 |
| 2010 | 217 |
| 2011 | 297 |
| 2012 | 1,094 |
| 2013 | 1,236 |
| 2014 | 1,653 |
| 2015 | 2,273 |
| 2016 | 2,335 |
| 2017 | 2,281 |
| 2018 | 3,063 |
| 2019 | 3,446 |
| 2020 | 2,766 |
| 2021 | 2,356 |
| 2022 | 2,181 |
| 2023 | 2,090 |
| 2024 | 2,138 |
| 2025 | 2,001 |
| 2026 | 1,537 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Cardiovascular effects of paroxetine.
Kuhs H, Rudolf GA · Psychopharmacology (Berl) 1990 · Clinical Trial, Comparative Study
- Cancer-related fatigue-pharmacological interventions: systematic review and network meta-analysis.
Chow R, Bruera E, Sanatani M, et al. · BMJ Support Palliat Care 2023 · Systematic Review, Network Meta-Analysis
- Pharmacological treatments for social anxiety disorder in adults: a systematic review and network meta-analysis.
Williams T, McCaul M, Schwarzer G, et al. · Acta Neuropsychiatr 2020 · Comparative Study, Network Meta-Analysis
- Efficacy and tolerability of second-generation antidepressants in social anxiety disorder.
Hansen RA, Gaynes BN, Gartlehner G, et al. · Int Clin Psychopharmacol 2008 · Network Meta-Analysis, Research Support, N.I.H., Extramural
- A systematic review and meta-analysis of randomized controlled trials of "on-demand" use of tramadol vs "on-demand" use of paroxetine in the management of patients with premature ejaculation.
Tan H, Zhou Z, Cui Y, et al. · Int J Clin Pract 2021 · Meta-Analysis, Systematic Review
- Paroxetine is an effective treatment for refractory erythema of rosacea: Primary results from the Prospective Rosacea Refractory Erythema Randomized Clinical Trial.
Wang B, Huang Y, Tang Y, et al. · J Am Acad Dermatol 2023 · Randomized Controlled Trial, Multicenter Study
Sponsor: Legacy
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.